Publications
Chosen filters:
Chosen filters:
Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts Vrije Universiteit Brussel
Challenges in conducting efficacy trials for new COVID-19 vaccines in developed countries Institute of Tropical Medicine
The protection from COVID-19 vaccination wanes a few months post-administration of the primary vaccination series or booster doses. New COVID-19 vaccine candidates aiming to help control COVID-19 should show long-term efficacy, allowing a possible annual administration. Until correlates of protection are strongly associated with long-term protection, it has been suggested that any new COVID-19 vaccine candidate must demonstrate at least 75% ...
Management of anaphylaxis due to COVID‐19 vaccines in the elderly Ghent University
Older adults, especially men and/or those with diabetes, hypertension and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritised to receive COVID-19 vaccines due to high risk of death. In very rare instances,the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS ...
Development, evaluation and use of COVID‐19 vaccines in older adults : preliminary principles for the pandemic and beyond Ghent University
The COVID-19 pandemic brought development, evaluation and use of vaccines for older adults into the spotlight. Here, we reflect on the gaps that were highlighted and strategies to fill them, during the pandemic and beyond. This commentary draws on principles we compiled through the geriatric pharmacology subcommittee of the clinical division of the International Union of Basic and Clinical Pharmacology (IUPHAR), to guide the regulation and use ...
Reply to 'Caution in underrepresentation of older adults in clinical trials on COVID-19 vaccines' Ghent University
We would like to thank Chen et al. for their comments on our recently published paper in Ageing Research Reviews (Veronese et al., 2021). In this reply we would like to answer to the points raised in their letter. Regarding the first question, we decided to run our search only in PubMed/Medline and ClinicalTrials.gov since the phase II-III randomized controlled trials of SARS-CoV 2 vaccines, considering the urgency for interventions to ...
Brugada syndrome and COVID-19 vaccines Vrije Universiteit Brussel
Assessing COVID-19 Vaccine's Acceptability Amongst Health Care Workers in Oman Institute of Tropical Medicine University of Antwerp
mRNA-lipid nanoparticle COVID-19 vaccines : structure and stability Ghent University
A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they have to be stored at (ultra)low temperatures. Understanding the root cause of the instability of these vaccines may help to rationally improve mRNA-LNP product stability and thereby ease the temperature conditions for storage. In this review we discuss proposed structures of mRNA-LNPs, factors that impact mRNA-LNP stability and strategies to optimize mRNA-LNP ...